



Press release
January 15, 2010

Likvor receives an order for CELDA™ from the University Hospital in Linköping

LinkMed's portfolio company Likvor has received an order for Likvor CELDA™ from the University Hospital in Linköping. With Likvor CELDA™ the clinic will be able to dynamic measure the most important parameters concerning the patients' cerebrospinal fluid including pressure and flow in a controlled and safe process. Likvor CELDA™ was developed to facilitate greater understanding and enhance diagnosis of normal pressure hydrocephalus (NPH), a condition that is often mistaken for dementia. This is the fourth order for the instrument since it got CE marked.

Likvor CELDA™ is the first commercially approved instrument for assessing the flow of CSF fluid that surrounds the brain and spinal cord. It increases the possibility for patients who suffer from NPH to receive a correct diagnosis and therefore the appropriate treatment in the form of a shunt implant that diverts and regulates CSF pressure and flow. An accurate diagnosis means large gains for the patient and family, but also for society as a whole.

Likvor CELDA™ is used with a special developed catheter, CELDA TOOLS™ that is a disposable for one time use only.

Hidden disease of old age

Normal Pressure Hydrocephalus (NPH) is a relatively unknown disease that is often mistakenly diagnosed as dementia, Alzheimer's or Parkinson's. The is because the symptoms, including disturbances in gait, confusion and urinary incontinence, are similar to those of dementia, plus that NPH is a condition that mainly occurs in people over the age of 55. Studies have shown that up to 10 percent of dementia patients may actually be suffering from NPH. In Sweden it is estimated that over 7,000 Swedes suffer from the disease – most of them unnecessarily. In the U.S., the corresponding figure is well over 375,000. NPH is a condition that is relatively easily treated by the insertion of a shunt, which helps the patient to regulate CSF flow and pressure.

Likvor's principal owners are Uminova Invest and LinkMed. For more information about Likvor, please visit www.likvor.com.

For more information please contact:

Kjell Öberg, CEO Likvor: +46 70 640 14 92
Okee Williams, Portfolio Manager LinkMed: +46 70 600 5364
Agneta Edberg, Head of Sales and Marketing Likvor +46 70 555 7518

LinkMed develops life science companies in collaboration with innovators and other financiers. By contributing management and capital, LinkMed has created a portfolio of thirteen companies, four in drug development and biotechnology and nine in diagnostics and medical technology. The company's principal shareholders are Mohammed Al Amoudi, FastPartner AB (publ), and Mannersons Fastighets AB. LinkMed is listed on the NASDAQ OMX Stockholm Exchange in the Small Cap section (ticker: LMED).